Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma

Abstract

It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently and were not different from the control group. No correlation was found between baseline prolactin levels and FSH, LH, p=0.658, p=0.817, p=0.760 respectively). In conclusion, beneficial metabolic changes were seen in patients with prolactinoma after treatment with cabergoline. Thus considering the metabolic profile and an appropriate treatment goal is important in the clinical management of patients with prolactinoma.